4894.T stock down 33.97% to JPY 7,230.00 at JPX close 24 Feb 2026: key risk signals
4894.T stock opened the JPX session on 24 Feb 2026 and closed down 33.97% at JPY 7,230.00 on heavy volume. The drop followed a gap from the previous close of JPY 10,950.00, with intraday range JPY 7,150.00 to JPY 7,900.00 and volume of 1,202,700.00 shares versus an average of 228,081.00. As a top loser on the Healthcare-biotechnology board, Cuorips Inc. (4894.T) shows stretched valuation metrics and volatile trading that require close monitoring for catalysts and downside protection.
4894.T stock: Price action and volume
Cuorips Inc. (4894.T) closed the JPX session at JPY 7,230.00, down 33.97% on 24 Feb 2026. Trading hit 1,202,700.00 shares, a relative volume of 14.82, well above the 50-day and 200-day averages. The stock opened at JPY 7,870.00 and traded between JPY 7,150.00 and JPY 7,900.00. The sudden selloff amplified intraday volatility and confirmed the security’s top-losers status for the session.
4894.T stock: Fundamentals and valuation
Cuorips (4894.T) reports EPS -81.54 and a negative PE of -102.04, reflecting current losses. Key balance-sheet metrics include cash per share JPY 460.62, book value per share JPY 610.43, and market capitalization of JPY 68,593,491,200.00. Price-to-book stands at 13.69 and price-to-sales at 192.85, indicating a valuation disconnect versus peers. Shares outstanding total 8,244,410.00, producing a thin free float and amplified price moves on heavy trades.
4894.T stock: Technical indicators and sector context
Technically, 4894.T shows mixed momentum. RSI sits near 47.09, MACD histogram is positive but narrowing, and ADX at 53.15 signals a strong trend — currently downward. The 50-day average is JPY 7,529.60 and the 200-day average is JPY 6,751.70, placing price between medium-term averages. In Healthcare (Biotechnology), sector average PE is about 23.43, so Cuorips’ negative earnings and high PB ratio stand out as valuation outliers.
4894.T stock: Meyka AI rates and forecast
Meyka AI rates 4894.T with a score out of 100: 68.95 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 10,167.79, implying an upside of 40.60% from the current JPY 7,230.00. Forecasts are model-based projections and not guarantees.
4894.T stock: Risks, catalysts and company signals
Key risks include persistent negative EPS, a high price-to-book ratio, and a recent companyRating of D+ (Strong Sell) dated 2026-02-20. Catalysts that could reverse sentiment are positive clinical updates, regulatory approvals, or new manufacturing contracts. Upcoming earnings are scheduled for 2026-05-20, which could re-rate the shares. Cash runway looks healthy given a current ratio of 37.06, but revenue and operating cash flow trends require monitoring.
4894.T stock: Trading strategy after a top-losers session
For traders, set clear scenario targets: bear-case support near the year low JPY 5,120.00, conservative target JPY 6,500.00, and base-case recovery target JPY 10,200.00. Day traders should note ATR of 918.89 and on‑balance volume near -64,900.00. Use tight position sizing and stop-losses due to the stock’s thin float and jump in relative volume. Investors should weigh upcoming clinical/regulatory milestones before adding exposure.
Final Thoughts
4894.T stock finished the JPX session on 24 Feb 2026 as one of the market’s top losers, falling to JPY 7,230.00 on a 33.97% drop and unusually high volume of 1,202,700.00 shares. Fundamentals show negative EPS (-81.54) and stretched valuation ratios, while technicals indicate a strong short-term trend. Meyka AI’s forecast model projects a yearly target of JPY 10,167.79, implying 40.60% upside from the close, but shorter-term quarterly projections imply downside risk. Given the mix of a healthy cash buffer, clinical development dependency, and a recent weak rating, we advise careful sizing and event-driven monitoring. Traders should watch the 2026-05-20 earnings date and any clinical readouts; these remain the primary catalysts for reversing today’s top-losers move. Meyka AI provides this as AI-powered market analysis; forecasts and grades are model-based and not guarantees.
FAQs
Why did 4894.T stock drop so sharply today?
4894.T stock fell 33.97% on 24 Feb 2026 amid heavy volume. The move reflects valuation concerns, negative EPS, and a weak company rating, combined with profit taking and a thin float that amplified selling pressure.
What are the key valuation metrics for 4894.T stock?
4894.T stock shows EPS -81.54, PE -102.04, PB 13.69, and price-to-sales 192.85. Cash per share is JPY 460.62 and book value per share is JPY 610.43, highlighting mixed balance-sheet strength and high market valuation.
What price targets should investors use for 4894.T stock?
For 4894.T stock consider bear support JPY 5,120.00, conservative recovery JPY 6,500.00, and base-case target JPY 10,200.00. Use event-driven risk controls ahead of the 2026-05-20 earnings announcement.
How reliable is the Meyka AI forecast for 4894.T stock?
Meyka AI’s forecast model projects JPY 10,167.79 for the year, implying 40.60% upside from JPY 7,230.00. Forecasts are model-based projections and not guarantees; they should supplement fundamental due diligence.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.